Should there be a role for sacubitril-valsartan in the management of patients with heart failure with preserved ejection fraction?

Would you consider adding sacubitril-valsartan to the medication regimens of patients with heart failure with preserved ejection fraction?

• Yes, but only in women based on reduction in primary outcome compared to men in PARAGON-HF
• No, given the lack of benefit in terms of lowering CV mortality and HF hospitalizations based on PARAGON-HF
• I would consider it in patients whose LVEF fluctuates between 45% and normal LV systolic function
• Other